TY - JOUR
T1 - Patient-reported toxicity during pelvic intensity-modulated radiation therapy
T2 - NRG oncology-RTOG 1203
AU - Klopp, Ann H.
AU - Yeung, Anamaria R.
AU - Deshmukh, Snehal
AU - Gil, Karen M.
AU - Wenzel, Lari
AU - Westin, Shannon N.
AU - Gifford, Kent
AU - Gaffney, David K.
AU - Small, William
AU - Thompson, Spencer
AU - Doncals, Desiree E.
AU - Cantuaria, Guilherme H.C.
AU - Yaremko, Brian P.
AU - Chang, Amy
AU - Kundapur, Vijayananda
AU - Mohan, Dasarahally S.
AU - Haas, Michael L.
AU - Kim, Yong Bae
AU - Ferguson, Catherine Lowrie
AU - Pugh, Stephanie L.
AU - Kachnic, Lisa A.
AU - Bruner, Deborah W.
N1 - Funding Information:
The human investigations were performed after approval by a local Human Investigations Committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services. Supported by National Cancer Institute Grants No. U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology Statistics and Data Management Center), and UG1CA189867 (National Cancer Institute Community Oncology Research Program).
Publisher Copyright:
© 2018 American Society of Clinical Oncology. All rights reserved.
PY - 2018/8/20
Y1 - 2018/8/20
N2 - Purpose: NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and healthrelated quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods: Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT, measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC). Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. Results: From 2012 to 2015, 289 patients were enrolled, of whom 278 were eligible. Between baseline and end of RT, the mean EPIC bowel score declined 23.6 points in the standard RT group and 18.6 points in the IMRT group (P = .048), the mean EPIC urinary score declined 10.4 points in the standard RT group and 5.6 points in the IMRT group (P = .03), and the mean Trial Outcome Index score declined 12.8 points in the standard RT group and 8.8 points in the IMRT group (P = .06). At the end of RT, 51.9% of women who received standard RT and 33.7% who received IMRT reported frequent or almost constant diarrhea (P = .01), and more patients who received standard RT were taking antidiarrheal medications four or more times daily (20.4% v 7.8%; P = .04). Conclusion: Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective.
AB - Purpose: NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and healthrelated quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods: Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT, measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC). Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. Results: From 2012 to 2015, 289 patients were enrolled, of whom 278 were eligible. Between baseline and end of RT, the mean EPIC bowel score declined 23.6 points in the standard RT group and 18.6 points in the IMRT group (P = .048), the mean EPIC urinary score declined 10.4 points in the standard RT group and 5.6 points in the IMRT group (P = .03), and the mean Trial Outcome Index score declined 12.8 points in the standard RT group and 8.8 points in the IMRT group (P = .06). At the end of RT, 51.9% of women who received standard RT and 33.7% who received IMRT reported frequent or almost constant diarrhea (P = .01), and more patients who received standard RT were taking antidiarrheal medications four or more times daily (20.4% v 7.8%; P = .04). Conclusion: Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective.
UR - http://www.scopus.com/inward/record.url?scp=85051814416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051814416&partnerID=8YFLogxK
U2 - 10.1200/JCO.2017.77.4273
DO - 10.1200/JCO.2017.77.4273
M3 - Article
C2 - 29989857
AN - SCOPUS:85051814416
SN - 0732-183X
VL - 36
SP - 2538
EP - 2544
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 24
ER -